Literature DB >> 15300331

[Muscular atrophy as a symptom].

J Schmiedel1, H Reichmann.   

Abstract

Muscular atrophy is a symptom characterized by the loss of normal muscle mass. It is caused by a decline in the total number of muscle cells, or by a substantial decline in the substance of individual muscle cells. It has been associated with a preceding muscle weakness. Muscular atrophy occurs late in the course of a disease. Due to the limited ability of muscle cells to regenerate, it is frequently irreversible. Hence the aim is to detect the early stages of muscular decline and to prevent outright muscular atrophy. To achieve this it is necessary to be aware of the large number of diseases that can induce this in order to ensure timely referral to a specialist.

Entities:  

Mesh:

Year:  2004        PMID: 15300331     DOI: 10.1007/s00108-004-1256-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

Review 1.  [Molecular diagnosis of hereditary neurologic diseases. Position paper].

Authors:  T Gasser; M Dichgans; K Jurkat-Rott; T Klockgether; T Klopstock; H Kretzschmar; F Lehmann-Horn; H Reichmann; A Rolfs; T Sander; F Stögbauer
Journal:  Nervenarzt       Date:  2000-10       Impact factor: 1.214

2.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

Review 3.  Orthopedic management of the muscular dystrophies.

Authors:  Twee Do
Journal:  Curr Opin Pediatr       Date:  2002-02       Impact factor: 2.856

4.  Cardiac involvement in myotonic dystrophy, Becker muscular dystrophy and mitochondrial myopathy: a five-year follow-up.

Authors:  J Finsterer; C Stöllberger; G Blazek; E Spahits
Journal:  Can J Cardiol       Date:  2001-10       Impact factor: 5.223

5.  The response of patients with Duchenne's muscular dystrophy to neuromuscular blockade with vecuronium.

Authors:  D G Ririe; F Shapiro; N F Sethna
Journal:  Anesthesiology       Date:  1998-02       Impact factor: 7.892

6.  [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types].

Authors:  E Breucking; P Reimnitz; U Schara; W Mortier
Journal:  Anaesthesist       Date:  2000-03       Impact factor: 1.041

Review 7.  The heart in human dystrophinopathies.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Cardiology       Date:  2003       Impact factor: 1.869

Review 8.  Neurotrophins and neurodegeneration.

Authors:  D Dawbarn; S J Allen
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

9.  Clinical results of early orthopaedic management in Duchenne muscular dystrophy.

Authors:  M Goertzen; A Baltzer; T Voit
Journal:  Neuropediatrics       Date:  1995-10       Impact factor: 1.947

Review 10.  Orthopedic management of neuromuscular disorders in children.

Authors:  J G Birch
Journal:  Semin Pediatr Neurol       Date:  1998-06       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.